Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

CollPlant Biotechnologies (CLGN) EBIT (2017 - 2025)

Historic EBIT for CollPlant Biotechnologies (CLGN) over the last 9 years, with Q3 2025 value amounting to -$3.5 million.

  • CollPlant Biotechnologies' EBIT rose 2278.73% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 20342.86%. This contributed to the annual value of -$17.3 million for FY2024, which is 12964.59% down from last year.
  • Per CollPlant Biotechnologies' latest filing, its EBIT stood at -$3.5 million for Q3 2025, which was up 2278.73% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, CollPlant Biotechnologies' EBIT peaked at $10.0 million during Q1 2021, and registered a low of -$5.1 million during Q4 2023.
  • Its 5-year average for EBIT is -$443789.5, with a median of -$3.1 million in 2021.
  • Data for CollPlant Biotechnologies' EBIT shows a peak YoY increase of 68734.62% (in 2021) and a maximum YoY decrease of 10042.15% (in 2021) over the last 5 years.
  • CollPlant Biotechnologies' EBIT (Quarter) stood at -$3.8 million in 2021, then fell by 22.92% to -$4.7 million in 2022, then fell by 8.38% to -$5.1 million in 2023, then rose by 21.59% to -$4.0 million in 2024, then grew by 11.75% to -$3.5 million in 2025.
  • Its EBIT stands at -$3.5 million for Q3 2025, versus $3.2 million for Q2 2025 and $1.6 million for Q1 2025.